2025-05-02 10:07:27
Latest Post
Godrej Agrovet Limited consolidated Q4FY25 net profit drops QoQ to Rs. 70.78 crores
L G Balakrishnan & Bros Ltd posts Rs. 84.03 crores consolidated profit in Q4FY25
Swastika Investmart Ltd Q4 FY2025 consolidated profit slumps to Rs. 27.17 lakhs
Vertex Securities Ltd consolidated Q4 FY25 loss at Rs. 53.99 lakhs
The Federal Bank Limited consolidated Q4FY25 PAT jumps to Rs. 1108.31 crores
Stock Report
Cadila Healthcare Ltd Q1FY22 consolidated net profit at Rs. 587.2 crore
Posted On : 2021-08-11 14:15:29( TIMEZONE : IST )
Cadila Healthcare Ltd. has reported financial results for the period ended June 30, 2021.
Financial Results (Q1 FY 2021-22) - QoQ Comparison
The company has reported total income of Rs.4057 crores during the period ended June 30, 2021 as compared to Rs.3661.8 crores during the period ended March 31, 2021.
The company has posted net profit / (loss) of Rs.587.2 crores for the period ended June 30, 2021 as against net profit / (loss) of Rs.679 crores for the period ended March 31, 2021.
The company has reported EPS of Rs.5.74 for the period ended June 30, 2021 as compared to Rs.6.63 for the period ended March 31, 2021.
| Financials | Q1 FY2021-22 | Q4 FY20-21 | % Change |
| Total Income | ₹ 4057 crs | ₹ 3661.8 crs |  10.79% |
| Net Profit | ₹ 587.2 crs | ₹ 679 crs |  -13.52% |
| EPS | ₹ 5.74 | ₹ 6.63 | -13.42% |
Financial Results (Q1 FY 2021-22) - YoY Comparison
The company has reported total income of Rs.4057 crores during the period ended June 30, 2021 as compared to Rs.3537.1 crores during the period ended June 30, 2020.
The company has posted net profit / (loss) of Rs.587.2 crores for the period ended June 30, 2021 as against net profit / (loss) of Rs.454 crores for the period ended June 30, 2020.
The company has reported EPS of Rs.5.74 for the period ended June 30, 2021 as compared to Rs.4.43 for the period ended June 30, 2020.
| Financials | Q1 FY2021-22 | Q1 FY2020-21 | % Change |
| Total Income | ₹ 4057 crs | ₹ 3537.1 crs | 14.7% |
| Net Profit | ₹ 587.2 crs | ₹ 454 crs | 29.34% |
| EPS | ₹ 5.74 | ₹ 4.43 | 29.57% |
The company's India business which comprises human formulations and consumer wellness business which contributed to 50% of consolidated revenues during the quarter, witnessed a very strong growth of 43% on a y-o-y basis, posting sales of Rs.1943 crores during the quarter. The company's business in the US posted sales of Rs. 1451 crores. The company's rest of the world business grew by 17% during the quarter on a y-o-y basis and posted sales of Rs. 277 crores.
The company's lead molecule Saroglitazar Mg, received 'Orphan Drug Designation' from the European Medicines Agency (EMA) for the treatment of patients with Primary Biliary Cholangitis (PBC). It provides a 10-year period of market exclusivity if the treatment is eventually approved. Earlier the USFDA had granted 'Orphan Drug Designation' and 'Fast Track Designation' to Saroglitazar Mg for PBC.
During the quarter, the company launched Trastuzumab Emtansine, the first Antibody Drug Conjugate (ADC) biosimilar and a highly effective drug for treating both Early and Advanced HER2 positive Breast Cancer under the brand name 'Ujvira'. The drug has significantly reduced the treatment cost by almost 80% for patients.
Continuing with its fight against the pandemic, the company has also undertaken research in monoclonal antibodies cocktail to neutralise COVID infection. The company initiated the clinical trials of its monoclonal antibodies cocktail that can neutralise COVID-19 infection. ZRC-3308, a cocktail of two SARS-CoV-2-neutralizing monoclonal antibodies (mAbs) can emerge as one of the main treatments for mild COVID 19. Zydus is the only Indian company to have developed a neutralizing monoclonal antibody based cocktail for the treatment of COVID 19.
Continuing with its efforts to provide easily accessible therapy to fight Black Fungus or Mucormycosis in India, Zydus and TLC a specialty pharmaceutical company in Taiwan signed a license supply and commercialization agreement to commercialize AmphoTLC™ (Amphotericin B Liposome for Injection 50mg) in India.
The company has also applied to DCGI for Emergency Use Authorization (EUA) for ZyCoVD, World's first Plasmid DNA Vaccine for human use after conducting the largest vaccine trial so far in India for COVID-19.
Shares of Cadila Healthcare Ltd. was last trading in BSE at Rs. 576.35 as compared to the previous close of Rs. 585.75. The total number of shares traded during the day was 183796 in over 3273 trades.
The stock hit an intraday high of Rs. 589.7 and intraday low of 573.55. The net turnover during the day was Rs. 107074589.
